Cell Therapeutics Selling $60M in Preferred Stock; Share Price Tumbles
Cell Therapeutics selling M in preferred stock; share price tumbles
Filed under: Seattle Drug Treatment
The Seattle biotech's stock tumbled nearly 25 percent after it said it plans to sell $ 60 million in preferred stock to raise money for the launch of its lymphoma drug Pixuvri and to fund studies of its drug pacritinib as a treatment for myelofibrosis …
Read more on The Seattle Times
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant …
Filed under: Seattle Drug Treatment
SEATTLE, Oct. 2, 2012 — /PRNewswire/ — Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced that OPAXIO (paclitaxel poliglumex) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment …
Read more on Sacramento Bee
More Seattle Drug Treatment Resources
Cell Therapeutics Selling $60M In Preferred Stock; Share Price Tumbles
The Seattle biotech’s stock tumbled nearly 25 percent after it said it plans to sell $60 million in preferred stock to raise money for the launch of its lymphoma drug Pixuvri and to fund studies of its drug pacritinib as a treatment for myelofibrosis. … Read News